ALERS — Eurobio Scientific SA Cashflow Statement
0.000.00%
- €248.69m
- €238.58m
- €154.56m
- 92
- 38
- 38
- 58
Annual cashflow statement for Eurobio Scientific SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | FAS | FAS | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 73.5 | 60.5 | 24.9 | 4.83 | 4 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.92 | 0.455 | -1.25 | 1.12 | 2.31 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -28.3 | -3.67 | 8.84 | 8.35 | -4.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 54.9 | 65.9 | 43.1 | 26.8 | 16.7 |
| Capital Expenditures | -2.3 | -1.85 | -2.83 | -4.05 | -3.26 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1.69 | -3.62 | -139 | 3.74 | -7.48 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.98 | -5.47 | -142 | -0.318 | -10.7 |
| Financing Cash Flow Items | -2.4 | -0.882 | -1.21 | -2.51 | 20.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 7.05 | -23.8 | 82.3 | -23.5 | -72.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 57.9 | 36.8 | -16.5 | 3.09 | -66 |